Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Metastatic renal cell carcinoma (mRCC) treatment is evolving, incorporating VEGF targeted therapies (TT), tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy.
• Optimizing patient outcomes necessitates the identification of genomic markers predictive of response to specific therapies.
• This study focuses on identifying tumor-based genomic markers to guide the selection of first-line VEGF TT for mRCC.

Purpose of the Study:

• To identify tumor-based genomic alterations (GAs) that predict progression-free survival (PFS) in patients with mRCC receiving first-line VEGF TT.
• To develop a composite model of genomic markers for improved prediction of treatment response.
• To inform personalized treatment strategies in mRCC.

Main Methods:

• Retrospective analysis of primary tumor tissue from 79 patients with clear cell mRCC.
• Targeted sequencing to identify genomic alterations (GAs).
• Correlation of GAs with progression-free survival (PFS) using Kaplan-Meier and Cox proportional hazard models.

Main Results:

• Absence of VHL mutation was significantly associated with inferior PFS on first-line VEGF TT.
• Genomic alterations in TP53 and the FLT1 C/C variant showed a trend towards inferior PFS.
• A composite model incorporating TP53 mutation, wild-type VHL, and FLT1 C/C variant predicted inferior PFS in a dose-dependent manner.

Conclusions:

• A composite model of TP53 mutation, wild-type VHL, and FLT1 C/C variant is a strong predictor of PFS in mRCC patients on first-line VEGF TT.
• This composite model demonstrates a dose-dependent relationship with PFS, suggesting its utility in treatment selection.
• External validation is required to confirm these findings and their clinical applicability.